« Back
Home /
Durvalumab

Durvalumab

Manufacturer	TargetMol
Category	Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Amount	5mg
Item no.	TMO-T11126-5mg
CASRN	1428935-60-7
eClass 6.1	32169090
eClass 9.0	32169090
Available
Short Description	Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.
Shipping	cool pack
Storage	-20°
Target names or alias	MEDI 4736
Pathway	Immunology/Inflammation\|\|\|Apoptosis\|\|\|Cell Cycle/Checkpoint
Target	PD-1/PD-L1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T11126-5mg-datasheet.pdf

TMO-T11126-5mg-safety-datasheet.pdf